Skip to search formSkip to main contentSkip to account menu

telatinib

National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

PyridazinesPyridines
Receptor Tyrosine Kinase InhibitionTelatinib Mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
chapter 4 – skin microvascular density and blood pressure Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib Anticancer Drugs
Hypertension is a common side-effect in cancer patients treated with inhibitors of VEGF/VEGFR-2 signaling and may represent a… 
2012
2012
The Observed Correlation between in vivo Clinical Pharmacokinetic Parameters and in vitro Potency of VEGFR-2 Inhibitors
Abstract Literature data on the clinical pharmacokinetics of various VEGFR-2 inhibitors along with in vitro potency data were… 
2011
2011
Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with…
4122 Background: Angiogenesis is essential for tumor growth and plays an important role in metastasis in gastrointestinal (GI… 
Review
2011
Review
2011
Onset of CT scan morphological changes in metastatic lesions and associated responses in gastric patients treated with telatinib.
81 Background: Response to the antiangiogenic agent, bevacizumab, by CT has been associated with a unique morphologic change in… 
2010
2010
Phase II study of telatinib (T) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced cancer of the stomach (G) or gastro-esophageal junction…
e14575 Background: Telatinib (T) is a potent small molecule oral tyrosine kinase inhibitor selectively targeting the VEGF and… 
2010
2010
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
3045 Background: Telatinib (BAY 57-9352) is an oral tyrosine kinase inhibitor targeting the vascular endothelial growth factor… 
2008
2008
Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors
2530 Background: Telatinib is an orally available, small molecule tyrosine kinase domain inhibitor of the VEGFR-2, VEGFR-3, PDGFR… 
2007
2007
A phase Ib study of telatinib (BAY 57–9352), a VEGFR-2 inhibitor, in combination with docetaxel in patients with advanced solid tumours
14035 Background: Telatinib (BAY 57–9352) inhibits VEGFR-2 and VEGFR-3 tyrosine kinases, and PDGFR-β and c-Kit. Preclinical data… 
2007
2007
A Phase Ib study of telatinib (BAY 57-9352), a VEGFR-2 inhibitor, in combination with docetaxel in patients with advanced solid tumors
B13 Background: Telatinib (BAY 57-9352) is an oral, multitargeted tyrosine kinase inhibitor of VEGFR-2, VEGFR-3, PDGFR-I² and c… 
2006
2006
72 POSTER Phase I, safety, pharmacokinetic and biomarker study of telatinib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)